西南大學生命科學學院教育部創新重點實驗室
使用zeta life,Advanced DNA RNA轉染試劑
高效率轉染HCT-116, SW480, HT-29人結直腸癌細胞
2020-4-28發表文章已見刊
發表文章轉染條件
A、HCT-116, SW480, HT-29人結直腸癌細胞
B、AURKA質粒
C、轉染細胞融合度50%
D、96孔板每孔使用0.5μg質粒DNA
6孔每孔使用10 ug質粒DNA
(注意:本實驗中用到的細胞密度、轉染質粒DNA用量不適用于LIPO3000/2000)
發表文章部分內容
Overexpression of AURKA Plasmid for AURKA overexpression was obtained from VectorBuilder. Details about plasmid containing the AURKA gene can be found at colon cancer cells (HCT-116, SW480, HT-29) were seeded at 50% confluency for 24 h in six-well and 96-well plates. Plasmid (10 ug per-well for six-well and 0.5 μg per-well for 96 plates) and the Advanced DNA RNA transfection(zeta life,USA) reagent were mixed in equal proportionsand added to the cell culture medium for 6 h. DOX (1 μg/ml) was added to induce the expression of AURKA. After addition of DOX and PAL for 36 h, cell viability was measured by MTT and apoptosis was detected by。
PAL exerts anti-colon cancer effects by targeting AURKA. (A) PAL promotes apoptosis in colon cancer cells (HCT-116, SW480) in a dose-dependent manner. (B) PAL promotes G2/M phase arrest in colon cancer cells (HCT-116, SW480) in a dose-dependent manner. (C) The expression of AURKA after DOX treatment for 24 h. (D) Cell density after PAL treatment for 24 h in the cells (HCT-116, SW480) transfected with AURKA overexpression plasmids. DOX is an inducer of AURKA
expression in plasmids. (E) Effect of PAL detected by MTT assay on the proliferation ability of colon cancer cells transfected with AURKA overexpression plasmids. (F) Effects of PAL detected by.
zeta life,Advanced DNA RNA轉染試劑信息如下:
產品名稱 | 貨號 | 規格 |
Advanced DNA RNA 轉染試劑 | AD600025 | 0.25ML |
Advanced DNA RNA 轉染試劑 | AD600050 | 0.5 |
Advanced DNA RNA 轉染試劑 | AD600075 | 0.75 |
Advanced DNA RNA 轉染試劑 | AD600150 | 1.5ML |
Advanced DNA RNA 轉染試劑 | AD600500 | 5ML |
Advanced DNA RNA 轉染試劑 | AD601000 | 10ML |
免責聲明
- 凡本網注明“來源:化工儀器網”的所有作品,均為浙江興旺寶明通網絡有限公司-化工儀器網合法擁有版權或有權使用的作品,未經本網授權不得轉載、摘編或利用其它方式使用上述作品。已經本網授權使用作品的,應在授權范圍內使用,并注明“來源:化工儀器網”。違反上述聲明者,本網將追究其相關法律責任。
- 本網轉載并注明自其他來源(非化工儀器網)的作品,目的在于傳遞更多信息,并不代表本網贊同其觀點和對其真實性負責,不承擔此類作品侵權行為的直接責任及連帶責任。其他媒體、網站或個人從本網轉載時,必須保留本網注明的作品第一來源,并自負版權等法律責任。
- 如涉及作品內容、版權等問題,請在作品發表之日起一周內與本網聯系,否則視為放棄相關權利。